...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Archives of Toxicology >Tissue distribution and toxicity of intravenously administered titanium dioxide nanoparticles in rats
【24h】

Tissue distribution and toxicity of intravenously administered titanium dioxide nanoparticles in rats

机译：静脉内施用二氧化钛纳米颗粒在大鼠中的组织分布和毒性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The tissue distribution and toxicity of intravenously administered nanoparticles of titanium dioxide (TiO2) (>10 wt.% at <100 nm size) were investigated because of the fundamental importance to obtain information on the kinetics of this widely used nanoparticle in a situation of 100% bioavailability. Male Wistar rats were treated with single intravenous injections of a suspension of TiO2 in serum (5 mg/kg body weight), and the tissue content of TiO2 was determined 1, 14, and 28 days later. Biochemical parameters and antigens in serum were also assessed to determine potential pathological changes. The health and behavior of the animals were normal throughout the study. There were no detectable levels of TiO2 in blood cells, plasma, brain, or lymph nodes. The TiO2 levels were highest in the liver, followed in decreasing order by the levels in the spleen, lung, and kidney, and highest on day 1 in all organs. TiO2 levels were retained in the liver for 28 days, there was a slight decrease in TiO2 levels from day 1 to days 14 and 28 in the spleen, and a return to control levels by day 14 in the lung and kidney. There were no changes in the cytokines and enzymes measured in blood samples, indicating that there was no detectable inflammatory response or organ toxicity. Overall, rats exposed to TiO2 nanoparticles by a route that allows immediate systemic availability showed expected tissue distribution, no obvious toxic health effects, no immune response, and no change in organ function. Therefore, even with 100% bioavailability of the 5 mg/kg TiO2 dose afforded by the intravenous route of administration, there were no remarkable toxic effects evident in the experimental animals. These results indicate that TiO2 nanoparticles could be used safely in low doses.
机译：研究了静脉内施用的二氧化钛（TiO2 ）（<100 nm尺寸> 10 wt。％）的组织分布和毒性，这是因为获得有关这种广泛使用的纳米颗粒动力学的信息的根本重要性。生物利用度为100％的情况。对雄性Wistar大鼠进行单次静脉内注射TiO2 在血清中的悬浮液（5 mg / kg体重）治疗，并在第1、14和28天后测定TiO2 的组织含量。还评估了血清中的生化参数和抗原，以确定潜在的病理变化。在整个研究过程中，动物的健康和行为均正常。在血细胞，血浆，脑或淋巴结中均未检测到TiO2 的水平。肝脏中TiO2 的含量最高，依次是脾脏，肺和肾脏的含量，并且在所有器官的第1天最高。肝脏中TiO2 的含量保留了28天，从第1天到第14天和第28天，脾脏中的TiO2 含量略有下降，到第14天时，又恢复到正常水平。肺和肾。血样中的细胞因子和酶没有变化，表明没有可检测到的炎症反应或器官毒性。总体而言，通过允许立即全身利用的途径暴露于TiO2纳米颗粒的大鼠显示出预期的组织分布，没有明显的毒性健康影响，没有免疫反应，并且器官功能没有变化。因此，即使通过静脉内给药途径提供的5 mg / kg TiO2 剂量具有100％的生物利用度，在实验动物中也没有明显的毒性作用。这些结果表明，TiO2 纳米颗粒可以低剂量安全使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号